sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 28, 2026

Starbucks (SBUX) Q1 2026 Earnings Call Transcript

View original at finance.yahoo.com
Starbucks (SBUX) Q1 2026 Earnings Call Transcript Image source: The Motley Fool. DATE Wednesday, January 28, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Brian R…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Protein platform showing high trial and repeat rates with high incrementality

    80% confidence
  • EPS guidance range of $2.15-$2.40 for FY2026

    80% confidence
  • Brand metrics including affinity, trust, and value perception are all improving

    80% confidence
  • China joint venture expected to close in Spring 2026 subject to regulatory approval

    80% confidence
  • First positive year-over-year transaction growth in 8 quarters for both Rewards and non-Rewards customers

    80% confidence
  • China joint venture expected to be approximately 40 basis points accretive to consolidated margins annually

    80% confidence
  • Customer feedback shows lowest complaint levels in 2+ years with improved speed and convenience perception

    80% confidence
  • Net new stores guidance of 600-650 globally for FY2026, including 150-175 U.S. company-operated and 450-500 international (with China approximately half)

    80% confidence
  • Global comparable store sales guidance of +3% or better for FY2026

    80% confidence
  • If joint venture structure assumed for full year FY2026, expect slightly lower revenue/comps, slightly better margins, and $0.02-$0.03 EPS dilution

    80% confidence
  • Target to complete 1,000+ coffeehouse uplifts by end of 2026

    80% confidence
  • Operating margins expected to show slight year-over-year growth with improvement in second half of FY2026

    80% confidence
  • Green Apron service standard has improved throughput with cafe and drive-through performance under 4-minute targets

    80% confidence
  • Approximately one-third of North America operating margin pressure in Q1 from product/distribution cost inflation related to tariffs and elevated coffee pricing

    80% confidence
  • Menu reduced by 25-30% as part of Back to Starbucks initiatives

    80% confidence
  • Thousands of identified U.S. sites for new Ristretto format stores

    80% confidence
  • All age cohorts and income groups increased visitation in Q1 FY2026

    80% confidence
  • $2B cost reduction target over next 2-3 years focusing on G&A, procurement, and technology efficiency

    80% confidence
  • 650 pilot stores under Back to Starbucks plan outperform fleet by approximately 200 basis points in comparable store sales, all transaction-driven

    80% confidence
  • U.S. comparable store sales guidance of +3% or better for FY2026

    80% confidence

Data points we hold from this source

Starbucks Corporation · operating margin change-180 basis points YoY
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Starbucks (SBUX) Q1 2026 Earnings Call Transcript — Source | Via News | pt.VIA.NEWS